Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Affimed N.V. (0HL9.L)
Mannheim, DE
Affimed N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer immunotherapies, with operations spanning the United States, Germany, and the rest of Europe. The company's primary investigational therapy, AFM13, has successfully completed a Phase II clinical study for peripheral T-cell lymphoma. This same candidate is also currently undergoing Phase IIa clinical trials for CD30-positive lymphoma and is in Phase I trials for Hodgkin lymphoma. Beyond its lead product, Affimed is advancing several other promising pipeline compounds. AFM24, a tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptors and CD16A, is presently in Phase IIa clinical trials for the treatment of various advanced cancers. Additionally, two other innate cell engagers (ICEs) are in preclinical development: AFM28, which is being investigated for acute myeloid leukemia, and AFM32, a candidate focused on the treatment of solid tumors. Affimed N.V. has formed strategic partnerships with esteemed institutions and companies, including The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. The company also receives research funding through an agreement with The Leukemia & Lymphoma Society. Founded in 2000, Affimed N.V. was initially known as Affimed Therapeutics B.V. before officially changing its name in October 2014. Its corporate headquarters are located in Heidelberg, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.60% | -100.00% | -99.99% | -99.96% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-67.4% Q3'24: -91.6% (vs Q3'23)
-
EPS growth Biotechnology: +29.7%-17.4% Q3'24: +42.3% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-761.7% Q3'24: -6,792.7% (vs Q3'23)
-
EBIT margin Biotechnology: +0.0%-744.5% Q3'24: -8,709.1% (vs Q3'23)
-
ROIC Biotechnology: -16.1%-268.2% Q3'24: -954.7% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+4.9% Q3'24: +7.8% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.19× Q3'24: -0.23× (vs Q3'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.76M
est: 3.06M (+23.1%)
|
8.21M
est: 7.79M (+5.5%)
|
6.49M
est: 6.94M (-6.5%)
|
2.21M
est: 3.01M (-26.7%)
|
23.73M
est: 1.70M (+1,295.3%)
|
21.43M
est: 19.44M (+10.2%)
|
28.86M
est: 32.12M (-10.2%)
|
41.55M
est: 38.74M (+7.3%)
|
42.67M
est: 37.09M (+15.0%)
|
13.91M
est: 9.57M (+45.4%)
|
1.73M
est.
|
967.4K
est.
|
1.98M
1.98M – 1.98M
+104.6% YoY
|
1.98M
1.98M – 1.98M
+0.0% YoY
|
1.98M
1.98M – 1.98M
+0.0% YoY
|
1.98M
1.98M – 1.98M
+0.0% YoY
|
| EBITDA |
-7.74M
est: -3.06M (-153.2%)
|
-21.01M
est: -7.79M (-169.8%)
|
-31.65M
est: -15.96M (-98.3%)
|
-26.92M
est: -13.10M (-105.6%)
|
-20.66M
est: -15.01M (-37.6%)
|
-31.72M
est: -208.83M (+84.8%)
|
-33.73M
est: -23.76M (-42.0%)
|
-62.82M
est: -50.00M (-25.6%)
|
-86.01M
est: -125.41M (+31.4%)
|
-102.59M
est: -209.45M (+51.0%)
|
-663.22M
est.
|
-967.4K
est.
|
-1.98M
-1.98M – -1.98M
-104.6% YoY
|
-1.98M
-1.98M – -1.98M
+0.0% YoY
|
-1.98M
-1.98M – -1.98M
+0.0% YoY
|
-1.98M
-1.98M – -1.98M
+0.0% YoY
|
| EBIT |
-8.18M
est: -3.06M (-167.6%)
|
-21.34M
est: -15.30M (-39.5%)
|
-32.02M
est: -18.12M (-76.7%)
|
-27.27M
est: -13.16M (-107.3%)
|
-21.06M
est: -12.45M (-69.2%)
|
-32.63M
est: -211.78M (+84.6%)
|
-34.85M
est: -24.41M (-42.8%)
|
-64.16M
est: -51.37M (-24.9%)
|
-86.74M
est: -128.85M (+32.7%)
|
-103.59M
est: -215.20M (+51.9%)
|
-681.43M
est.
|
-967.4K
est.
|
-1.98M
-1.98M – -1.98M
-104.6% YoY
|
-1.98M
-1.98M – -1.98M
+0.0% YoY
|
-1.98M
-1.98M – -1.98M
+0.0% YoY
|
-1.98M
-1.98M – -1.98M
+0.0% YoY
|
| Net Income |
-259.0K
est: -258.16M (+99.9%)
|
-20.24M
est: -486.4K (-4,061.1%)
|
-32.22M
est: -17.18M (-87.5%)
|
-30.22M
est: -13.23M (-128.5%)
|
-19.48M
est: -13.80M (-41.1%)
|
-32.37M
est: -211.14M (+84.7%)
|
-41.37M
est: -24.40M (-69.5%)
|
-57.52M
est: -51.36M (-12.0%)
|
-86.00M
est: -128.81M (+33.2%)
|
-105.94M
est: -215.12M (+50.8%)
|
-681.20M
est.
|
-25.99M
est.
|
-27.77M
-27.77M – -27.77M
-6.9% YoY
|
-24.15M
-24.15M – -24.15M
+13.0% YoY
|
-19.47M
-19.47M – -19.47M
+19.4% YoY
|
-10.72M
-10.72M – -10.72M
+45.0% YoY
|
| SGA |
2.59M
est: 3.25M (-20.4%)
|
7.82M
est: 7.30M (+7.1%)
|
8.62M
est: 7.38M (+16.8%)
|
7.99M
est: 3.20M (+149.5%)
|
9.64M
est: 1.81M (+432.6%)
|
10.27M
est: 20.69M (-50.4%)
|
13.72M
est: 9.23M (+48.5%)
|
24.22M
est: 19.44M (+24.6%)
|
32.08M
est: 39.47M (-18.7%)
|
24.68M
est: 10.18M (+142.3%)
|
1.40M
est.
|
786.0K
est.
|
1.61M
1.61M – 1.61M
+104.6% YoY
|
1.61M
1.61M – 1.61M
+0.0% YoY
|
1.61M
1.61M – 1.61M
+0.0% YoY
|
1.61M
1.61M – 1.61M
+0.0% YoY
|
| EPS |
-0.15
est: -17.28 (+99.1%)
|
-7.11
est: -6.87 (-3.5%)
|
-9.69
est: -10.80 (+10.3%)
|
-6.91
est: -6.72 (-2.8%)
|
-3.22
est: -5.98 (+46.1%)
|
-5.04
est: -4.91 (-2.7%)
|
-4.96
est: -3.17 (-56.7%)
|
-4.81
est: -4.66 (-3.3%)
|
-6.04
est: -5.69 (-6.2%)
|
-7.09
est: -7.37 (+3.8%)
|
-4.06
est.
|
-1.74
est.
|
-1.86
-1.86 – -1.86
-6.9% YoY
|
-1.62
-1.62 – -1.62
+13.0% YoY
|
-1.30
-1.30 – -1.30
+19.4% YoY
|
-0.72
-0.72 – -0.72
+45.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wolfgang Fischer | MD, Chief Operating Officer, Chief Strategy Officer & Member of Management Board | 632.0K | — |
| Andreas Harstrick | Chief Medical Officer & Member of Management Board | 522.8K | — |
| Alexander Fudukidis | Head of Investor Relations & Director of Investor Relations | — | male |
| Mary Beth Sandin | Vice President of Marketing & Communications | — | — |
| Melvyn Little | Founder & Consultant | — | — |
| Michael Wolf | Head of Finance & Administration | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0HL9.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
